JAK inhibitor provides rapid, durable relief for myelofibrosis patients

An oral medication produces significant and lasting relief for patients with myelofibrosis, a debilitating and lethal bone marrow disorder, researchers at The University of Texas MD Anderson Cancer Center report in the Sept. 16 New England Journal of Medicine.

Read the whole article on Physorg

More from Physorg